SCHEMBL18151063

SCHEMBL18151063

COc1ccccc1C1COCC(=O)N1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
USP2 O75604 1/20 0.44
CYP19A1 P11511 1/20 0.44
POLB P06746 2/20 0.42
HTR2C P28335 3/20 0.42
ALDH1A1 P00352 7/20 0.41
HPGD P15428 4/20 0.41
TDP1 Q9NUW8 4/20 0.41
LMNA P02545 3/20 0.41
TSHR P16473 1/20 0.41
PKM P14618 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2B P41595 1/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 4/20 0.39
MASP2 O00187 1/20 0.39
GAPDH P04406 1/20 0.39
HSPA1A P0DMV8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18151062 1.00 L3MBTL1 (0.50) L3MBTL1KMT2AMEN1USP2CYP19A1
SCHEMBL25238773 0.85 ATM (0.47) L3MBTL1KMT2AMEN1HTR2CALDH1A1
SCHEMBL18162840 0.82 HTR2C (0.42) L3MBTL1KMT2AMEN1USP2CYP19A1
SCHEMBL18150779 0.82 ALDH1A1 (0.47) L3MBTL1KMT2AMEN1ALDH1A1LMNA
SCHEMBL16796807 0.82 ALDH1A1 (0.47) L3MBTL1KMT2AMEN1ALDH1A1LMNA
SCHEMBL16796809 0.82 ALDH1A1 (0.47) L3MBTL1KMT2AMEN1ALDH1A1LMNA
SCHEMBL1438817 0.79 CYP19A1 (0.49) L3MBTL1KMT2AMEN1USP2CYP19A1
SCHEMBL1438815 0.79 CYP19A1 (0.49) L3MBTL1KMT2AMEN1USP2CYP19A1
SCHEMBL29144899 0.79 CYP19A1 (0.49) L3MBTL1KMT2AMEN1USP2CYP19A1
SCHEMBL1193829 0.78 CTSB (0.36) KMT2AMEN1TDP1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266532-B2 Tricyclic modulators of TNF signaling ABBVIE INC. (US) 2019-04-23 US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 L3MBTL1 4129/4885KMT2A 4542/4885MEN1 2587/4885
US-10266532-B2 Tricyclic modulators of TNF signaling TNF, TNFRSF1A, CD40 L3MBTL1 4129/4885KMT2A 4542/4885MEN1 2587/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 L3MBTL1 4129/4885KMT2A 4542/4885MEN1 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.